Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

All Drugs and Chemicals

Antineoplastic Agents

Antibodies

Antibodies, Monoclonal

Docetaxel

Immunomodulating Agents

Immunoglobulins

Tubulin Modulators

Antimitotic Agents

Docetaxel \& PD1-T cells

Docetaxel,60mg/m2,intravenous infusion,d1; PD1-T cells, 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W.

Docetaxel

Docetaxel,60mg/m2,intravenous infusion,d1; Q3W.

PD1-T cells

Xiubao Ren, MD. PhD.

Liang Liu, MD.

Qian Sun, Ph.D

This study evaluates the effect and safty of PD-1 monoclonal antibody-activated autologous peripheral blood T-lymphocyte (PD1-T) combined with docetaxel in the second-line treatment of IIIB/IIIC/IV non-small cell lung cancer. Half of participants receive PD1-T combined with docetaxel, while the other half will receive docetaxel.

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer

Phase III Clinical Study of PD-1 Monoclonal Antibody-activated Autologous Peripheral Blood T-Lymphocyte (PD1-T) Combined With Docetaxel in the Second-line Treatment of IIIB/IIIC/IV Non-small Cell Lung Cancer

PFS will be calculated from initiation of treatment until first progression, and patients alive in stable state will be censored at the time of last contact.

Tianjin Medical University Cancer Institute and Hospital

Digestive System Diseases

Rare Diseases

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)

D2+ surgery(D2+8p、12b、13、14v lymph node)

surgery

xiangdong Cheng, MD

xiangdong Cheng

The purpose of this study is to evaluate the safety and the effect of D2 and D2+ radical surgery for the treatment of advanced distal gastric cancer.

To evaluate the safety and the disease-free survival time(DFS) and overall survival time(OS) of D2 and D2+ radical surgery for the treatment of advanced distal gastric cancer.

D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer

Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer

Zhejiang Cancer Hospital

Skin and Connective Tissue Diseases

Breast Neoplasms

Acute Graft Versus Host Disease

Antirheumatic Agents

Anti-Inflammatory Agents

Anti-Infective Agents

Trastuzumab

Carboplatin

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Triamcinolone

Triamcinolone Acetonide

Triamcinolone hexacetonide

Triamcinolone diacetate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Antineoplastic Agents, Immunological

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)

Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy

Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy

Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy

Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy

4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Standard Dose Dense Doxorubucin and Cyclophosphamide

4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Standard Doxorubucin and Cyclophosphamide

6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Standard Docetaxel, Carboplatin, and Herceptin

3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Standard Docetaxel, Doxorubucin and Cyclophosphamide

4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).

Standard Docetaxel and Cyclophosphamide

Richard Zellars, M.D.

Amit Shah, M.D.

Breast conserving therapy, (BCT), which consists of wide local excision of the tumor followed by 6 weeks of whole breast irradiation, (WBI), is integral to the management of breast cancer. Evidence now suggests that WBI may not be necessary and treatment to the involved area only, partial breast irradiation, (PBI), may suffice. PBI can be achieved by interstitial or intracavitary brachytherapy, intra-op, or post op external beam radiation therapy. The feasibility, toxicity and efficacy of PBI are currently being studied in both the U.S. and Europe. Review of smaller studies suggests that PBI will prove to be comparable to WBI. Chemotherapy combined with radiation has been shown to increase local control in BCT when compared to radiation alone. However there is little data on how sequencing or timing of these therapies with respect to one another affect outcome. As a result there is no consensus about the optimal combination. There are real and potential benefits to concurrent chemo-radiation therapy. Concurrent therapy 1) allows both treatments to start closer to surgery, theoretically maximizing the benefits of each modality; 2) shortens the overall treatment program; and 3) may also improve local control via chemo-sensitization of residual cancer cells. However, concurrent chemotherapy and WBI have been associated with prohibitive skin toxicity. Since less breast tissue is treated with PBI, this skin toxicity may no longer be prohibitive. We have shown in J0381 that PBI and concurrent dose dense AC is safe. As a follow-up, we propose a phase I/II trial addressing the toxicity and efficacy associated with PBI delivered concurrently with various chemotherapy regimens.

1. Partial Breast Irradiation with concurrent chemotherapy (various regimens. Subjects will receive Segmental Mastectomy (Lumpectomy)
2. Medical Oncology Evaluation
3. Consent/Registration Pre-RT evaluation
4. Simulation/Treatment Planning
5. Chemo-Radiation Therapy:

   ddAC, Std AC, TAC, TC, TCH or TH Concurrent with PBI - (270 cGy per fraction for 15 fractions). RT may start up to 7days prior to C1D1, but no later than 7 days after C1D1 (+/- 7 days of C1D1 radiation may start)
6. Further chemotherapy, hormonal therapy or biologic therapy at the medical oncologist's discretion
7. F/U Schedule

Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens

"A Feasibility Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (PBIC)"

Acute Skin toxicity will be scored on a scale ranging from 0-4, where a higher score reflects more severe toxicity:

0= no change; 1= follicular, fain or dull erythema/epilation/dry/desquamation/decreased swelling; 2= tender or bright erythemal patchy moist desquamation/moderate edema; 3= confluent moist desquamation other than skin folds, pitting edema; 4= ulceration, hemorrhage, necrosis.

Late Skin toxicity will be scored on a scale ranging from 0-4, where a higher score reflects more severe toxicity:

0= none; 1= slight atrophy, pigmentation change, some hair loss; 2= patchy atrophy, moderate telangiectasias, total hair loss; 3= marked atrophy, gross telangiectasias; 4= ulceration

Subcutaneous tissue toxicity will be scored on a scale ranging from 0-4, where a higher score reflects more severe toxicity:

0= none; 1= slight induration (fibrosis) and loss of subcutaneous fat; 2= moderate fibrosis but asymptomatic; slight field contracture; \<10% linear reduction; 3= severe induration and loss subcutaneous tissue; field contracture \>10% linear reduction; 4= necrosis

Number of participants with Poor, Fair, Good, or Excellent cosmetic effect after PBIC. Cosmetic effect will be graded by the investigator and participant as specified by the grading criteria in the Study Protocol (grading criteria description too large for this field).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer	NCT03944980	IIIB/IIIC/IV Lu...	Docetaxel PD1-T cells	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer	NCT03944980	IIIB/IIIC/IV Lu...	Docetaxel PD1-T cells	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer	NCT01836991	Gastric Cancer	surgery	18 Years - 70 Years	Zhejiang Cancer Hospital
Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens	NCT00681993	Breast Cancer	Standard Dose D... Standard Doxoru... Standard Doceta... Standard Doceta... Standard Doceta...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer	NCT01836991	Gastric Cancer	surgery	18 Years - 70 Years	Zhejiang Cancer Hospital

Spots Global Cancer Trial Database for effect

Every month we try and update this database with for effect cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for effect

Every month we try and update this database with for effect cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for effect cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.